Becton Dickinson - Biotech, Pharma and Life Science Channel
Becton Dickinson is one of the top 10 medical device companies in the world. It reported annual sales of just over $7 billion in 2010, and quarterly trends have seen encouraging increases.
Some of the products it supplies to the medical industry includes disposable equipment such as syringes, needles and surgical blades , as well as diagnostic tools such as devices for sampling blood and for disease screening.
The company is furthering its work in bacterial and fungal identification and antimicrobial susceptibility testing, through a collaboration with Bruker Daltonics.
Source; Adapted from Fierce BioTech and Becton Dickinson
Add the Becton Dickinson News Channel to your RSS reader;
News Articles
Retractable Technologies, Inc. Reports Results of Operations
Retractable Technologies, Inc. (NYSE MKT: RVP) reports the following results of operations for the first quarter of 2013. Comparison of Three Months Ended March 31, 2013...
BD Announces Results For 2013 Second Fiscal Quarter
FRANKLIN LAKES, N.J., May 2, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the...
Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology
At the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker shows new capabilities of the MALDI Biotyper™ platform. "Professor Da...
BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement
SPARKS, Md., April 27, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to s...
CytoVas And BD Biosciences Ink Alliance To Co-Develop Personalized Diagnostic For Vascular Health
PHILADELPHIA, April 25, 2013 /PRNewswire-iReach/ -- CytoVas, LLC and BD Biosciences, a division of BD (Becton, Dickinson and Company), announced today they have formed a strategic alliance to jo...
FDA Approves Second Drug in BD Simplist™ Prefilled Injectable Line of Products
FRANKLIN LAKES, N.J., April 23, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE:BDX), announced to...
Drug Delivery Technology Market worth $224.2 Billion By 2017
DALLAS, April 22, 2013 /PRNewswire/ -- The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pump...
Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
FRANKLIN LAKES, N.J., April 17, 2013 /PRNewswire/ -- While the Occupational Safety and Health Administration (OSHA) has classified chemotherapy drugs – which are designed to be toxic and hi...
BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS™ Passive Needle Guard
FRANKLIN LAKES, N.J., April 11, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the comm...
Study: Random Drug Testing of Middle School Students Proves Effective In Preventing Substance Abuse
ATLANTIC CITY, N.J., April 9, 2013 /PRNewswire-USNewswire/ -- The Partnership for a Drug-Free New Jersey (PDFNJ) and Fairleigh Dickinson University's PublicMind, today, released the results of their s...
Events
None
Companies
Apriso is a software company dedicated to helping its customers transform their global manufacturing operations. It does so by enabling manufacturers to achieve and sustain manufa...
Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...
Clinical Trials
A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer
1. To establish a retrospective compilation of clinical, histopathological, treatment and follow-up (clinic pathological) data of previous non-small cell lung cancer (NSCLC) case...
PubMed Articles
The whole blood lysis method has become a standard procedure to remove red cells prior to immunophenotypic analysis of leukocytes. In the present study we investigated the influence of four different...
BACKGROUND: The St Louis Cord Blood Bank submitted a biologics license application for cord blood (CB) products processed by PrepaCyte-CB (BioE), supported with a validation study of a microbial detec...
ABSTRACT: BACKGROUND: Smear microscopy, a mainstay of tuberculosis (TB) diagnosis in developing countries, cannot differentiate M. tuberculosis complex from NTM infection, while pulmonary TB shares cl...
Female athletes are at 3.5 times risk of sustaining a non-contact ACL injury compared with males. Research has shown that this gender discrepancy results from differences in neuromuscular adaptations...
HIV-seropositive individuals with low cognitive reserve are at high risk for developing HIV-associated neurocognitive disorders (HAND). The present study evaluated the hypothesis that cognitive reserv...
On page 2344, J. L. West, M. E. Dickinson, and co-workers demonstrate an image-guided method for engineering complex biomimetic materials. Using laser scanning microscopes and twophoton photolithograp...
Aims and objectives. The study aimed to examine the experiences of patients and meanings attached to 'treatments' of sexual deviations, which included homosexuality and transvestism, in the UK (194...
Research suggests that attention is attracted to evolutionary threats (e.g., snakes) due to an evolved "fear-module" that automatically detects biological threats to survival. However, recent evidence...
Relapses do not matter in relation to long-term disability: No (they do).
G. Bigras, J. Wilson, L. Russell, G. Johnson, D. Morel and M. Saddik Interobserver concordance in the assessment of features used for the diagnosis of cervical atypical squamous cells and squamous int...
Videos
2011 BD Executive Video
Edward J. Ludwig and Vincent A. Forlenza discuss 2011 at BD (Becton, Dickinson and Company).
